Preoperative (Neoadjuvant) or Postoperative (Adjuvant) Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer
Upon determination of eligibility, neo-adjuvant patients will be randomly assigned to one of
two treatment arms:
- ARM A Paclitaxel + Carboplatin + Radiation Therapy + Surgery
- ARM B Paclitaxel + Carboplatin + Surgery
After surgery neo-adjuvant patients with a complete resection will either receive Paclitaxel
+ Carboplatin or no therapy, depending on their stage of disease at time of enrollment.
Patients with incomplete resection Paclitaxel + Carboplatin + Radiation Therapy. Adjuvant
patients who enter the study after complete resection will receive Paclitaxel + Carboplatin
with or without Radiation Therapy based on initial stage of disease.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rates
Anthony Greco, MD
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LUN 53